TITLE

Developmental exposure to fenproporex: reproductive and morphological evaluation

AUTHOR(S)
Moreira, C. Q.; Faria, M. J. S. S.; Baroneza, J. E.; Oliveira, R. J.; Moreira, E. G.
PUB. DATE
August 2005
SOURCE
Human & Experimental Toxicology;Aug2005, Vol. 24 Issue 8, p397
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This study was designed to evaluate the maternal toxicity and teratogenicity of fenproporex, one of the most widely-used anorectic drugs in many countries, including Brazil. Three periods of exposure were evaluated: (a) 30 days before mating; (b) from gestational day (GD) 0 to 14; and (c) 30 days before mating and during pregnancy, until GD 14. Female mice from experimental groups received, by gavage, 15 mg/kg of fenproporex. Treatment with fenproporex increased ambulation of dams in the open-field test and did not influence the mobility in the forcedswimming test. There was no significant difference in maternal weight gain between the controls and fenproporex-treated groups, although fenproporex treatment reduced the gravid uterus weight. No significant difference was observed in postimplantation loss, fetal viability and sex ratio. In addition, this compound did not impair intra-uterine growth. The reduction in the number of implantations in the groups receiving fenproporex indicates that this drug may have an adverse effect on implantation. Fenproporex treatment also increased the number of fetuses presenting small kidneys and cervical ribs. The present results indicate that fenproporex, in the dose and exposure periods tested, appears to exhibit a low maternal toxicity and teratogenic potential in mice.
ACCESSION #
17671233

 

Related Articles

  • Gebelikte Psikotrop Ä°laç Kullanımı: Bir Güncelleme. Çetin, Mesut // Klinik Psikofarmakoloji Bulteni;Jun2011, Vol. 21 Issue 2, p161 

    Pregnancy is a turbulent period, during which hormonal and psychosocial lifestyle changes occur. Hence depression, anxiety disorders, or obsessive-compulsive disorders can be triggered and chronic psychiatric disorders can be exacerbated, particularly, due to limitations on the use of...

  • Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist. Ousten, BW van; Killeslein, J; Malbus-Vliegen, EMH; Polman, CH // Multiple Sclerosis (13524585);Jun2004, Vol. 10 Issue 3, p330 

    Laboratory research including animal models of human disease suggests that cannabinoids might have therapeutic potential in multiple sclerosis (MS). We have recently seen a 46-year-old woman who developed MS after starting treatment with a cannabinoid receptor antagonist for obesity. The...

  • In utero exposure to erythromycin may cause CV malformations.  // Reactions Weekly;7/23/2005, Issue 1061, p2 

    Reports on the advice of the Swedish Medical Products Agency regarding the administration of erythromycin during the early stages of pregnancy. Background on a study that suggest that in utero exposure to erythromycin may increase the risk of congenital cardiovascular (CV) malformations;...

  • Allopurinol Use during Pregnancy - Outcome of 31 Prospectively Ascertained Cases and a Phenotype Possibly Indicative for Teratogenicity. Hoeltzenbein, Maria; Stieler, Katja; Panse, Mary; Wacker, Evelin; Schaefer, Christof // PLoS ONE;Jun2013, Vol. 8 Issue 6, p1 

    Allopurinol is a purine analogue that inhibits xanthine oxidase. It is mainly used for the treatment of hyperuricemia in patients with gout or tumor lysis syndrome. Experience with allopurinol in pregnancy is scarce. In 2011, Kozenko et al. reported on a child with multiple malformations after...

  • High Dose Zolpidem Induced Fetal Neural Tube Defects. Sharma, Avinash; Sayeed, Neha; Khess, Christoday R. J.; Akhtar, Sayeed // Current Drug Safety;Apr2011, Vol. 6 Issue 2, p128 

    Use of zolpidem, a short-acting imidazopyridine hypnotic, has not been associated with teratogenic effects in usual clinical doses. We report a case of fetal neural tube defects occurring in a female dependent on zolpidem and consuming high doses in the first trimester of pregnancy. Possible...

  • A Possible Association between Oral Aminophylline Treatment during Pregnancy and Skeletal Congenital Abnormalities. Czeizel, Andrew E.; Puhó, Erzsebet; Bártfai, Zoltán; Somoskövi, Ákos // Clinical Drug Investigation;2003, Vol. 23 Issue 12, p803 

    Objective: To study the human teratogenic potential of oral aminophylline treatment during pregnancy. Design and setting: The analysis of each case and its matched controls, as well as comparison of population or patient controls and cases with 25 groups of congenital abnormalities in the...

  • Therapies for OBESITY and Medication-Associated Weight Gain. Howland, Robert H. // Journal of Psychosocial Nursing & Mental Health Services;May2013, Vol. 51 Issue 5, p13 

    Compared to the general population, individuals with psychiatric illness, especially serious and chronic mood and psychotic disorders, are more likely to be overweight or obese, have higher rates of weight-related medical conditions, and have greater non-suicide mortality rates. Lorcaserin...

  • Pharmacology of Appetite Suppression: Implication for the Treatment of Obesity. Halford, Jason C.G. // Current Drug Targets;Dec2001, Vol. 2 Issue 4, p353 

    Given the current global epidemic of obesity there is a demand for new anti-obesity drugs to overcome the problem. Many pharmacological agents reduce food intake and significantly decrease body mass when administered to animals but affect feeding behaviour in a profoundly different way...

  • Risks of miscarriage and inadvertent exposure to artemisinin derivatives in the first trimester of pregnancy: a prospective cohort study in western Kenya. Dellicour, Stephanie; Desai, Meghna; Aol, George; Oneko, Martina; Ouma, Peter; Bigogo, Godfrey; Burton, Deron C.; Breiman, Robert F.; Hamel, Mary J.; Slutsker, Laurence; Feikin, Daniel; Kariuki, Simon; Odhiambo, Frank; Pandit, Jayesh; Laserson, Kayla F.; Calip, Greg; Stergachis, Andy; ter Kuile, Feiko O. // Malaria Journal;11/18/2015, Vol. 14 Issue 1, p1 

    Background: The artemisinin anti-malarials are widely deployed as artemisinin-based combination therapy (ACT). However, they are not recommended for uncomplicated malaria during the first trimester because safety data from humans are scarce. Methods: This was a prospective cohort study of women...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics